Wedbush Downgrades Stemline Therapeutics (STML) to Neutral, Following Acquisition

May 4, 2020 12:19 PM EDT
Get Alerts STML Hot Sheet
Price: $11.83 --0%

Rating Summary:
    6 Buy, 4 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 22 | Down: 26 | New: 45
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Wedbush analyst David Nierengarten downgraded Stemline Therapeutics (NASDAQ: STML) from Outperform to Neutral with a price target of $12.50 (from $11.00).

For an analyst ratings summary and ratings history on Stemline Therapeutics click here. For more ratings news on Stemline Therapeutics click here.

Shares of Stemline Therapeutics closed at $4.75 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades